Clearance of a fluconazole-resistant Candida albicans strain after switching antifungal therapy and initiation of triple therapy for HIV infection.
Ruhnke
M
M
Department of Medicine, Universitätsklinikum Charité Campus Virchow Klinikum, Humboldt Universität zu Berlin, Berlin, Germany. markus.ruhnke@charite.de
Adler
A
A
Müller
F M
FM
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000382:microbiology; D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002176:Candida albicans / Q000187:drug effects*; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D016172:DNA Fingerprinting; D004352:Drug Resistance, Microbial; D015725:Fluconazole / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests
D000935:Antifungal Agents; D015725:Fluconazole